Dr. Mark B. Juckett, MD
Hematology (Hematology (Internal Medicine) Physician)
- Medicare participating
At a glance
- Years since graduation
- 39
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 64
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology (Internal Medicine) Physician primary
WI license 35344 -
Hematology & Oncology Physician
WI license 35344 -
Internal Medicine Physician
WI license 35344 -
Medical Oncology Physician
WI license 35344
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- M Health Fairview University of Mn Medical Center Minneapolis, MN
- M Health Fairview St John's Hospital Maplewood, MN
- M Health Fairview Ridges Hospital Burnsville, MN
- Fairview Northland Regional Hospital Princeton, MN
Medical groups
- Fairview Express Care (1,911 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 64
- Services billed
- 296
- Patients’ average age
- 67
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 71 | 35 |
| Established patient office or other outpatient visit, 30-39 minutes | 52 | 33 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 39 | 18 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Minneapolis, MN | 179 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Minneapolis, MN | 75 |
| Jakafi (ruxolitinib phosphate) | 74 |
| Posaconazole | 25 |
| Ursodiol Other prescribers in Minneapolis, MN | 23 |
| Prednisone Other prescribers in Minneapolis, MN | 22 |
| Dexamethasone Other prescribers in Minneapolis, MN | 22 |
| Pomalyst (pomalidomide) | 21 |
| Pantoprazole Sodium Other prescribers in Minneapolis, MN | 21 |
| Venclexta (venetoclax) | 21 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 3 payments worth $409 in total to this clinician.
| National Marrow Donor Program | $325 |
|---|---|
| Medexus Pharma, Inc. | $83.63 |
| Food and Beverage | $409 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $169,486 in research payments for these studies, mostly to the institutions running them.
- A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide as GvHD Prophylaxis in Adult Patients with Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplant…
National Marrow Donor Program - A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)
AbbVie Inc. · Terminated · NCT04161885 - M19-063 - A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.